News
`Select
`
`V
`
`Mylan Launches Generic Zosyn® Injection
`
`Print
`
`HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ - Mylan N.V. (Nasdaq:
`MYL) today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g
`Single -dose Vials, which Is the generic version of Pfizer's Zosyn® Injection. This product Is a
`combination penicillin -class antibacterial and beta- lactamase inhibitor indicated for the treatment of
`patients with moderate to severe infections caused by susceptible isolates of certain bacteria.
`
`Piperacillin and Tazobactam for Injection USP, 3.375g Single -dose Vials had U.S. sales of
`approximately $72.1 million for the 12 months ending June 30, 2015, according to IMS Health. Mylan's
`launch of this product adds to the company's growing portfolio of more than 145 injectable products
`available to patients in the U.S. across a broad array of therapeutic categories Including oncology, anti -
`infectives, anesthesla/pain management and cardiovascular.
`
`Currently, Mylan has 267 ANDAS pending FDA approval representing $101.3 billion in annual brand
`sales, according to IMS Health. Fifty of these pending ANDAs are potential first -to -file opportunities,
`representing $33.4 billion in annual brand sales, for the 12 months ending December 31, 2014,
`according to IMS Health.
`
`Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working
`together around the world to provide 7 billion people access to high quality medicine, we innovate to
`satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy;
`and impact the future through passionate global leadership. We offer a growing portfolio of around
`1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of
`antiretroviral therapies, upon which nearly 50% of HIV /AIDS patients in developing countries depend.
`We also operate one of the largest active pharmaceutical ingredient manufacturers and currently
`market products in about 145 countries and territories. Our workforce of approximately 30,000 people
`is dedicated to creating better health for a better world, one person at a time. Learn more at
`mylan.com.
`
`This press release includes statements that constitute "forward -looking statements," including with
`regard to the company's strategy, future growth and performance. These statements are made
`pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because
`such statements inherently involve risks and uncertainties, actual future results may differ materially
`from those expressed or implied by such forward -looking statements. Factors that could cause or
`contribute to such differences include, but are not limited to: the impacts of competition; changes in
`economic and financial conditions of the company's business; strategies by competitors or other third
`parties to delay or prevent product introductions; risks inherent in legal and regulatory processes;
`
`NCI Exhibit 2042
`
`

`
`uncertainties and matters beyond the control of management; and the other risks detailed in the
`company's filings with the Securities and Exchange Commission. The company undertakes no
`obligation to update these statements for revisions or changes after the date of this release.
`
`SOURCE Mylan N.V.
`
`For further information: Nina Devlin (Media), 724.514.1968; or Kris King (Investors), 724.514.1813